There is less data on the long-term efficacy and safety of these agents beyond one year and outside Ruxolitinib nmr of strict inclusion and exclusion criteria of pivotal randomized controlled trials (RCT). Here we aimed to document the long-term efficacy and safety of IFX and ADA in IBD in a regional setting. Methods: Patients with IBD who had received IFX or ADA from 1st January 2000 to 1st April 2012 were identified retrospectively from medical records at Launceston General Hospital and one gastroenterologist’s private practice (BM). Standard induction regimens
with IFX 5 mg/kg at week 0, 2 and 6 followed by 8-weekly maintenance or ADA 160 mg at week 0, 80 mg at week 2 then 40 mg fortnightly maintenance were used. Relevant patient data were extracted from medical records, with clinical outcomes
assessed using the treating physician’s global assessment of disease Palbociclib clinical trial activity after induction at 3 months and at end of follow-up. Patients were assessed for inclusion/exclusion criteria from published RCTs of IFX (ACCENT-I, ACCENT-II, SONIC, REACH, ACT-I and ACT-II) and ADA (CHARM and CLASSIC-1). Data are presented as mean and standard deviation [SD] or proportions. Results: 68 patients with records sufficiently detailed for analysis were identified (mean age 38 years [15], 56 CD, 12 UC). There were 54 anti-TNF naive CD patients (51 received IFX, 3 ADA) and 2 anti-TNF experienced CD patients (1 received IFX, 1 ADA). 23 (43%) anti-TNF naive CD patients went on to receive second-line anti-TNF due to loss of response, intolerance or patient choice. All 12 UC patients received IFX. At baseline, 19 (34%) CD patients had prior resection surgery, 9 (16%) were smokers, and 38 (68%) and 32 (57%) received concomitant immunomodulator and steroid therapy respectively. In anti-TNF naive CD, 15 (28%) received induction only, 32 (59%)
had induction and maintenance and 7 (13%) had episodic therapy. Induction response and steroid-free remission rates with first-line TNF were 91% and 48% respectively. After a mean duration of 34 months [33], sustained Methane monooxygenase response and steroid-free remission rates were 63% and 46% respectively. Of 25 anti-TNF experienced CD patients, induction response and steroid-free remission rates were 86% and 56% respectively and after a mean duration of 16 months [14], response and steroid-free remission rates were sustained in 68% and 46% respectively. In UC patients at baseline, 11 (92%) had severe disease, 7 (58%) had pancolitis and 7 (58%) and 11 (92%) were on concomitant immunomodulator and steroid therapy respectively. With IFX (5 induction only, 5 induction and maintenance and 2 episodic), induction response and steroid-free remission rates were 75% and 8% respectively and long-term sustained response and steroid-free remission were both 67% after a mean duration of 30 months [21]. 25 (45%) CD patients required escalation or change of biologic therapy and 14 (26%) CD patients and 3 (25%) UC required resection surgery during follow up.